UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
|
Date
of Report (Date of earliest event reported):
|
January
15, 2009
|
Renhuang
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other
jurisdiction
of incorporation)
|
|
O-24512
(Commission
File
Number)
|
|
88-1273503
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No.
281, Taiping Road, Taiping District,
Harbin,
Heilongjiang Province, 150050
P.
R. China
(Address
of principal executive offices) (zip code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
86-451-5762-0378
(Registrant’s
telephone number, including area code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
4.01 Changes in Registrant’s Certifying Accountant
On January 9, 2009, Renhuang
Pharmaceuticals, Inc. (the “Company” or “we”) dismissed Schwartz Levitsky
Feldman, LLP (“Schwartz”) as our principal independent accountant. Schwartz issued an Independent
Auditor’s Report on the financial statements of the Company for the fiscal year
ended October 31, 2007 and the six months ended October 31, 2006. Schwartz also
reviewed the interim financial statements of the Company’s indirect wholly-owned
subsidiary, Harbin Renhuang Pharmaceutical Stock Co., Ltd, a company
incorporated in the People’s Republic of China, for the six months ended April
30, 2006.
During
the fiscal year ended October 31, 2007 and six months ended October 31, 2006,
and through January 9, 2009, (i) there were no disagreements between the Company
and Schwartz on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedure which, if not resolved to
the satisfaction of Schwartz would have caused Schwartz to make reference to the
matter in its reports on the Company’s financial statements, and (ii) Schwartz’s
reports on the Company’s financial statements did not contain an adverse opinion
or disclaimer of opinion, nor were they modified as to audit scope or accounting
principles. During the fiscal year ended October 31, 2007 and six months ended
October 31, 2006 and through January 9, 2009, there were no reportable events as
that term is described in Item 304(a)(1)(iv) of Regulation S-K.
On
January 9, 2009, the Board of Directors appointed Moore Stephens, P.C. as the
principal independent accountant. The Company’s Board of Directors
participated in and approved the decision to change principal independent
accountant.
On
January 12, 2009, we provided Schwartz with a copy of this Form 8-K, and
requested that Schwartz furnish us with a letter addressed to the Securities and
Exchange Commission stating whether or not it agrees with the above statements
within ten (10) business days of the filing of this Form 8-K. We received such
letter on January 14, 2009. A copy of such letter, dated January 14, 2009 is
filed as Exhibit 16.1 to this Form 8-K.
Item 9.01 Financial Statements and
Exhibits.
(c)
Exhibits
|
16.1
|
Letter
of Schwartz Levitsky Feldman, LLP, dated January 14,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Dated: January
15, 2009
|
Renhuang
Pharmaceuticals, Inc.,
|
|
|
a
Nevada corporation
|
|
|
|
|
|
|
|
|
/s/
Shaoming Li
|
|
|
By: Shaoming
Li
|
|
|
Its: Chief
Executive Officer
|